IDIOPATHIC PULMONARY FIBROSIS MARKET ANALYSIS

Global idiopathic pulmonary fibrosis market is estimated to be valued at US$ 3,853.6 million in 2022 and is expected to exhibit a CAGR of 8.7% during the forecast period (2022-2030).

Analysts' Views on Global Idiopathic Pulmonary Fibrosis Market:

Global idiopathic pulmonary fibrosis market growth is expected to witness growthover the forecast period, owing to increasing adoption of inorganic growth stratergies such as collaboration by the key market players. For instance, in January 2022, BenevolentAI, a clinical-stage AI (Artificial Intellegence) drug discovery company, expanded its AI-driven drug discovery collaboration with AstraZeneca, a pharmaceutical company. The three-year expansion includes an upfront payment, research funding, development milestone payments, and agreement on future revenues. Through  this collaboration, will further help in expansion of  the ongoing  research work to identify multiple novel targets in chronic kidney disease (CKD) and idiopathic pulmonary fibrosis (IPF) will take place in future.

Figure 1. Global Idiopathic Pulmonary Fibrosis Market Share (%), By Drug, 2022

To learn more about this report, request sample copy

Global Idiopathic Pulmonary Fibrosis Market- Driver

Increasing research and development activities by market players for the treatment of patients suffering from idiopathic pulmonary fibrosis

Increasing focus on research and development activities in idiopathic pulmonary fibrosis market by the key market players is expected to drive the market growth. Moreover, adoption of advanced technologies such as artificial intelligence platform, and increasing  emerging strategies such as research and development acativities and others in the markets can create favorable opportunities for the idiopathic pulmonary fibrosis market growth. For instance, in June 2021, Sunshine Lake Pharma Co., Ltd., a manufacturing company, announced the initiation of clinical trial to study the efficacy and safety of various doses of HEC585 Tablets  with Pirfenidone in patients with idiopathic pulmonary fibrosis. This clinical trial is currenly in phase 2.

Figure 2. Global Idiopathic Pulmonary Fibrosis Market Share (%), By Region, 2022

To learn more about this report, request sample copy

Global Idiopathic Pulmonary Fibrosis Market- Regional Analysis

Among region, North America is expected to dominate the market over the forecast period, owing toNorth America 37.8% market share, and increasing cases of idiopathic pulmonary fibrosis in the U.S. For instance, in December 2020, according to the American IPF Foundation, the incidence of idiopathic pulmonary fibrosis (IPF) has doubled in the last ten years (2010-2020). In the U.S., approximately 50,000 people die from IPF every yearthat is higher than death rate from breast cancer.

Global Idiopathic Pulmonary Fibrosis Market – Impact of Coronavirus (COVID-19) Pandemic

Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). According to the World Health Organization (WHO), as of March 12, 2023,  4.1 Million people are affected worldwide.

COVID-19  resulted in several challenges to manage non-communicable diseases, especially to ensure continuity of treatment during the pandemic period. It has significantly affected healthcare systems and economies within a short timeframe. Furthermore, the unprecedented demand for hospital services during the COVID-19 pandemic has drastically reduced the capability for dealing with non-acute health needs including idiopathic pulmonary fibrosis.

COVID-19 had a positive impact on the global idiopathic pulmonary fibrosis market, owing to incline in number of idiopathic pulmonary fibrosis patient visits in hospitals & clinics for idiopathic pulmonary fibrosis therapy (IPF), as these patients suffering from idiopathic pulmonary fibrosis are more vulnerable to get infected by COVID-19 infection which lead to increase in demand for idiopathic pulmonary fibrosis products.

Global Idiopathic Pulmonary Fibrosis Market- Segmentation

Global idiopathic pulmonary fibrosis market report is segmented into drug, route of administration and distribution channel.

Based on Drug, the market is segmented into pirfenidone, nintedanib, and others (interferon gamma-1b and others). out of which, pirfenidone segment is expected to dominate the idiopathic pulmonary fibrosis market over the forecast period, owing to increasing collaboration between the key market players.

Based on Route of Administration, the global idiopathic pulmonary fibrosis market is segmented into oral and parenteral. The oral segment is expected to dominate the market over the forecast period, owing to increasing product launches by the key market players.

Based on Distribution Channel, the global idiopathic pulmonary fibrosis market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to dominate the market over the forecast period, due to increasing cases of  people suffering from idiopathic pulmonary fibrosis globally.

Among route of adminstration segment, the oral segment has the highest growth as market players are focusing on adopting of various growth strategies such as product launches, and this is expected to fuel the market growth over the forecast period. For instance, in May 2022, Sandoz, a global generic and biosimilar medicines manufacturing company, announced the U.S. launch of its oral pirfenidonethat is used for the treatment of patients suffering from idiopathic pulmonary fibrosis (IPF). This oral pirfenidone medicine is available to patients via specialty pharmacies with a zero fee program for patients.

Global Idiopathic Pulmonary Fibrosis Market- Cross-Sectional Analysis

On the basis of drug, pirfenidone held the dominant position in North America region, due increasing prevalence of idiopathic pulmonary fibrosis (IPF). For instance, on February 4, 2023, according to the report published by BMC Pulmonary Medicine,a part of Springer Nature, Idiopathic Pulmonary Fibrosis (IPF) is the most common of the Interstitual Lung Diseases (ILDs) that affects 14,000 to 15,000 people in Canada every year, and is common in males over the age of 50.

Furthermore, increasing research and development activities by the key market players for treatment of patients suffering from Idiopathic Pulmonary Fibrosis is boosting the market growth. For instance, in July 2022, Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, announced that INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF), announced positive data

Global Idiopathic Pulmonary Fibrosis Market- Key Developments

On January 16, 2023, Lotus Pharmaceutical, a multinational pharmaceutical company, announced that the U.S. Food and Drug Administration (U.S. FDA) has granted a tentative approval for the company's abbreviated new drug application (ANDA) for Nintedanib Capsules, the generic version of Boehringer Ingelheim’s OFEV (nintedanib).

In November 2022, Camber Pharmaceuticals, a subsidury of Hetero, a India-based pharmaceutical company, announced the addition of pirfenidone tablets to their product portfolio  that can be used  for the treatment of idiopathic pulmonary fibrosis (IPF).

In July 2022, Celix Pharma, a generic medicines manufacturing company, announced the launch of Pirfenidone 267mg, 801mg Film-coated Tablets in the U.K. The 267mg is available in blister packs of 63 and 252 tablets, whereas the 801mg is available in a blister pack of 84 tablets.

In July 2022, PureTech, a biopharmaceutical company, announced that it  had initiated a clinical study to evaluate the safety and effectiveness of its experimental therapy LYT-100 in people with idiopathic pulmonary fibrosis (IPF). LYT-100 also called as deupirfenidone  is a chemically-modified version of the approved IPF treatment Esbriet (pirfenidone) that is marketed by Genentech, Inc.,a biopharmaceutical company.

Global Idiopathic Pulmonary Fibrosis Market- Restraint

Side effects associated with the drugs such as enidone, nintedanib and others (interferon gamma-1b and others) for the tretament of patients suffering from idiopathic Pulmonary Fibrosis

The major factors that can hamper the growth of the global idiopathic pulmonary fibrosis market over the forecast period include side effects associated with the drugs that are used in the treatment. Pirfenidone causes serious side effects such as rash, extreme tiredness, unusual bleeding or bruising, lack of energy, loss of appetite, and others

For instance,  on February 1, 2023, according to the report published by Mayo Foundation for Medical Education and Research (MFMER), Nintedanib (Oral Route) can cause  side effects such as

• Dark urine
• Diarrhea
• Loss of appetite
• Nausea
• Pain or tenderness in the upper stomach
• Pale stools
• Severe stomach pain
• Vomiting
• Yellow eyes or skin

However, lack of awareness and unavailability of proper treatment for IPF is expected to restrain the growth of the idiopathic pulmonary fibrosis market during the forecast period.

Whease on the other hand to decline these side effects releated to drug used in the treatment of idiopathic pulmonary fibrosis, patients can consult their respecetive consultant or physician and timely have a look on the dose prescribed

Global Idiopathic Pulmonary Fibrosis Market- Key Players

Major players operating in the global idiopathic pulmonary fibrosis market include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.

Global Idiopathic Pulmonary Fibrosis Market– Insights

Pulmonary fibrosis is a pathogenic procedure associated with scarring of lung interstitium. Interstitial lung diseases (ILDs) encompass a large and heterogenous group of disorders that are characterized by progressive pulmonary fibrosis, and canlead to respiratory failure or even lead to death. Idiopathic pulmonary fibrosis (IPF)  is described as an archetype of progressive fibrosing ILD, and the development of pirfenidone and nintedanib has been a major breakthrough in the treatment of patients with this deadly disease.